Behavioural and neurochemical changes induced by stress-related conditions are counteracted by the neurokinin-2 receptor antagonist saredutant

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 813-823

  Tamburella, Alessandra ^a   Leggio, Gian Marco ^a   Micale, Vincenzo ^a   Navarria, Andrea ^a   Bucolo, Claudio ^a   Cicirata, Valentina ^a   Drago, Filippo ^a   Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Brain derived neurotrophic factor; corticosterone; forced swim test; NK 2 receptor antagonist; restraint stress

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; CORTICOSTERONE; FENCLONINE; SAREDUTANT;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; FORCED SWIMMING TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION STRESS; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; HIPPOCAMPUS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MOTOR ACTIVITY; PIPERIDINES; PITUITARY-ADRENAL SYSTEM; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-2; STRESS, PSYCHOLOGICAL;

EID: 84875737992     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000612     Document Type: Article

References (55)

1. Borelli KG, Defensor EB, Blanchard DC, Blanchard RJ, et al. (2010). Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery. Neuroscience Letters 485, 241-245.
2. Bradford MM (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72, 248-254.
3. Bramham CR, Messaoudi E (2005). BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Progress in Neurobiology 76, 99-125.
4. Briones-Aranda A, Lopez-Rubalcava C, Picaro O (2002). Influence of forced swimming-induced stress on the anxiolytic-like effect of 5HT(1A) agents in mice. Psychopharmacology 162, 147-155.
5. Chaki S, Nakazato A, Kennis L, Nakamura M, et al. (2004). Anxiolytic-and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. European Journal of Pharmacology 485, 145-158.
6. Consoli D, Fedotova J, Micale V, Sapronov NS, et al. (2005). Stressors affect the response of male and female rats to clomipramine in a model of behavioral despair (forced swim test). European Journal of Pharmacology 520, 100-107.
7. Consoli D, Leggio GM, Mazzola C, Micale V, et al. (2007). Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs? European Journal of Pharmacology 573, 139-147.
8. Cryan JF, Page ME, Lucki I (2005). Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology 182, 335-344.
9. Culman J, Das G, Ohlendorf C, Haass M, et al. (2010). Blockade of tachykinin NK1/NK2 receptors in the brain attenuates the activation of corticotrophin-releasing hormone neurones in the hypothalamic paraventricular nucleus and the sympathoadrenal and pituitary-adrenal responses to formalin-induced pain in the rat. Journal of Neuroendocrinology 22, 467-476.
10. de Kloet ER, Joëls M, Holsboer F (2005). Stress and the brain: from adaptation to disease. Nature Reviews Neuroscience 6, 463-475.
11. Drago F, Nicolosi A, Micale V, Lo Menzo G (2001). Placebo affects the performance of rats in models of depression: is it a good control for behavioural experiments? European Neuropsychopharmacology 11, 209-213.
12. Duman RS, Malberg J, Thome J (1999). Neural plasticity to stress and antidepressant treatment. Biological Psychiatry 46, 1181-1191.
13. Griebel G, Perrault G, Soubrié P (2001). Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 158, 241-251.
14. Gottmann K, Mittmann T, Lessmann V (2009). BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Experimental Brain Research 199, 203-234.
15. Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005). Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 1201-1213.
16. Hesketh S, Jessop DS, Hogg S, Harbuz MS (2005). Differential actions of acute and chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint stress. Journal of Endocrinology 185, 373-382.
17. Jacobson LH, Cryan JF (2007). Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behavior Genetics 37, 171-213.
18. Jensen JB, Jessop DS, Harbuz MS, Mørk A, et al. (1999). Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. Journal of Neuroendocrinology 11, 465-471.
19. Jéquier E, Lovenberg W, Sjoerdsma A (1967). Tryptophan hydroxylase inhibition: the mechanism by which p-chlorophenylalanine depletes rat brain serotonin. Molecular Pharmacology 3, 274-278.
20. Kolber BJ, Muglia LJ (2009). Defining brain region-specific glucocorticoid action during stress by conditional gene disruption in mice. Brain Research 1293, 85-90.
21. Kunugi H, Hori H, Adachi N, Numakawa T (2010). Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry and Clinical Neurosciences 64, 447-459.
22. Lanfumey L, Mongeau R, Cohen-Salmon C, Hamon M (2008). Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neuroscience and Biobehavioral Reviews 32, 1174-1184.
23. Louis C, Stemmelin J, Boulay D, Bergis O, et al. (2008). Additional evidence for anxiolytic-and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacology, Biochemistry and Behavior 89, 36-45.
24. Luo C, Xu H, Li XM (2004). Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Research 1025, 194-202.
25. McEwen BS (2005). Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54, 20-33.
26. McLaughlin KJ, Gonez JL, Baran SE, Conrad CD (2007). The effects of chronic stress on hippocampal morphology and function: an evaluation of chronic restraint paradigms. Brain Research 1161, 56-64.
27. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult hippocampus. Journal of Neuroscience 20, 9104-9110.
28. Micale V, Arezzi A, Rampello L, Drago F (2006). Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission. European Neuropsychopharmacology 16, 538-545.
29. Micale V, Scapagnini G, Colombrita C, Mazzola C (2008a). Behavioral effects of dietary cholesterol in rats tested in experimental models of mild stress and cognition tasks. European Neuropsychopharmacology 18, 462-471.
30. Micale V, Tamburella A, Leggio GM, Mazzola C, et al. (2008b). Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacology, Biochemistry and Behavior 90, 463-469.
31. Nibuya M, Nestler EJ, Duman RS (1996). Chronic antidepressant administration increases the expression of cAMP element binding protein (CREB) in rat hippocampus. Journal of Neuroscience 16, 2365-2372.
32. Overstreet DH, Naimoli VM, Griebel G (2010). Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Pharmacology, Biochemistry and Behavior 96, 206-210.
33. Page ME, Detke MJ, Dalvi A, Kirby LG, et al. (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147, 162-167.
34. Pintér O, Domokos A, Mergl Z, Mikics E, et al. (2011). Do stress hormones connect environmental effects with behavior in the forced swim test? Endocrine Journal 58, 395-407.
35. Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33, 88-109.
36. Porsolt RD, Bertin A, Jalfre M (1978). 'Behavioural despair' in rats and mice: strain differences and the effects of imipramine. European Journal of Pharmacology 51, 291-294.
37. Ribeiro RL, De Lima TC (2002). Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26, 861-869.
38. Risbrough VB, Stein MB (2006). Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Hormones and Behavior 50, 550-561.
39. Rittenhouse PA, López-RubalcavaC, Stanwood GD, Lucki I (2002). Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat. Psychoneuroendocrinology 27, 303-318.
40. Rogacki N, Lopez-Grancha M, Naimoli V, Potestio L, et al. (2011). The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. Pharmacology, Biochemistry and Behaviour 98, 405-411.
41. Salomé N, Stemmelin J, Cohen C, Griebel G (2006). Selective blockade of NK2 or NK3 receptors produces anxiolytic-and antidepressant-like effects in gerbils. Pharmacology, Biochemistry and Behavior 83, 533-539.
42. Sandford JJ, Argyropoulos SV, Nutt DJ (2000). The psychobiology of anxiolytic drugs. Part 1: basic neurobiology. Pharmacology and Therapeutics 88, 197-212.
43. Scharfman H, Goodman J, Macleod A, Phani S, et al. (2005). Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Experimental Neurology 192, 348-356.
44. Schmidt HD, Duman RS (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology 18, 391-418.
45. Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, et al. (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience 22, 3251-3261.
46. Steinberg R, Alonso R, Griebel G, Bert L, et al. (2001). Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. Journal of Pharmacology and Experimental Therapeutics 299, 449-458.
47. Stemmelin J, Canolle B, Roudières V, Labie C, et al. (2008). Saredutant (SR48968), a NK2 receptor antagonist, blocks chronic stress-induced decrease in neurogenesis in Balb/c mice. European Neuropsychopharmacology 18(S4), S356.
48. Stratton SC, Beresford IJ, Harvey FJ, Turpin MP (1993). Anxiolytic activity of tachykinin NK2 receptor antagonist in the mouse light-dark box. European Journal of Pharmacology 250, 11-12.
49. Tamburella A, Micale V, Leggio GM, Drago F (2010). The beta3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes. European Neuropsychopharmacology 20, 704-713.
50. Tamburella A, Micale V, Navarria A, Drago F (2009). Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33, 1205-1210.
51. Tardito D, Perez J, Tiraboschi E, Musazzi L, et al. (2006). Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic, mechanisms in the action of antidepressants: a critical overview. Pharmacological Reviews 58, 115-134.
52. Teixeira RM, De Lima TCM (2003). Involvement of tachykinin NK1 receptor in the behavioral and immunological responses to swimming stress in mice. Neuropeptides 37, 307-315.
53. Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, et al. (1995). The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology 121, 186-191.
54. Warner-Schmidt JL, Duman RS (2006). Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16, 239-249.
55. Xu H, Richardson JS, Li XM (2003). Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 28, 53-62.